Veracyte is a molecular diagnostics company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs. We specifically target diseases that often require invasive procedures for an accurate diagnosis – diseases where many patients undergo costly interventions that ultimately prove unnecessary. We improve the accuracy of diagnosis at an earlier stage of patient care by deriving clinically actionable genomic information from cytology samples collected in an outpatient setting.
Our first commercial solution, the Afirma® Thyroid FNA Analysis, centers on our Gene Expression Classifier (GEC), and is used in thyroid nodule assessment. The GEC helps physicians spare patients from unnecessary surgeries by employing a proprietary 142-gene signature to preoperatively determine whether thyroid nodules previously deemed by cytopathology as indeterminate can be reclassified as benign.
In April 2015, we launched our second genomic test, the Percepta Bronchial Genomic Classifier, for use in lung cancer diagnosis. The Percepta test uses advanced genomic technology to help patients avoid unnecessary invasive, risky procedures on suspicious lung nodules or lesions that were initially found on computed tomography (CT) scans.
Our common stock is listed on The NASDAQ Global Market under the symbol VCYT.
Jun 9, 2015 at 7:30 AM CT
May 18, 2015 at 6:00 AM MT
May 14, 2015 at 5:00 PM ET
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.